FindTrial
Sign In

Open clinical study on the efficacy and tolerability of buprenorfina tds transtec as first line opioid W.H.O. ladder s 3rd step for the medium-long term pain treatment in patients with solid advanced tumors

Open clinical study on the efficacy and tolerability of buprenorfina tds transtec as first line opioid W.H.O. ladder s 3rd step for the medium-long term pain treatment in patients with solid advanced tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-003703-36-IT
Enrollment
Unknown
Registered
2007-02-01
Start date
2005-04-13
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medium-long term treatment of pain in patients with solid advanced tumors

Interventions

Trade Name: N02AE01 Buprenorfina - Transtec 5Cer 20mg 35MCG/H Product Name: buprenorfina Pharmaceutical Form: Transdermal patch INN or Proposed INN: Buprenorphine CAS Number: 52485-79-7 Current Sponso

Sponsors

OSPEDALE FATEBENEFRATELLI E OFTALMICO DI MILANO
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026